2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
5
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Colorectal Neoplasms
3
Sarcoma
2
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Stage IIIb and IV Non Small Cell Lung Cancer
1
Solid Tumor, Adult
1
Rare Diseases
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Microsatellite Instability
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Genetic Predisposition to Disease
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Medullary
1
COVID-19
1
Biliary Tract Neoplasms
1
Interventions
Imatinib Mesylate
142
nilotinib
94
Cyclophosphamide
91
fludarabine phosphate
75
fludarabine
67
Dasatinib
63
Mycophenolic Acid
60
Whole-Body Irradiation
59
Tacrolimus
47
Busulfan
45
Cyclosporine
36
Peripheral Blood Stem Cell Transplantation
35
Cytarabine
35
Melphalan
30
bosutinib
27
ponatinib
26
Granulocyte Colony-Stimulating Factor
26
thymoglobulin
25
Thiotepa
25
Methotrexate
25
Filgrastim
25
asciminib
24
Antilymphocyte Serum
24
Stem Cell Transplantation
22
Sirolimus
17
Interferon-alpha
16
sargramostim
15
Cord Blood Stem Cell Transplantation
14
Clofarabine
13
Bone Marrow Transplantation
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT05605379
2024-08-14
CML Piramid
University Hospital, Bordeaux
Recruiting
88 enrolled